ææ¥ç§å°éå»ã®è³æ ¼ãæã¤å¤ç§å»ã§ããã¢ã¤ãã«å¥½ãã§ãã®ã§ã¢ã¤ãã«ãã¿ãæ¸ãã¦ãã¾ãï¼é常ã«æã ï¼ãå¥ã®æã«ææ¥ç§å°éå»ã®è©¦é¨åé¡ã®è§£èª¬ãå ¬éãã¦ãã¾ãã è¶ ä¹ ãã¶ãã®æ´æ°ã§ããFBããã¦ãããããããã¡ãã«ã¯ãã¾ãã¢ãããã¾ããã§ãããã¿ã¾ããã å¿èºèçã®è¬ç¿ä¼ãªã©ã§ãã·ã§ãã¯å¯è½ãªå¿èºåæ¢ã®å ´åã«ãã¢ããªããã³ã¯1åç®300mgãæä¸ã§ã追å ãå¿ è¦ã§ããã°150mgãæä¸ããã¨ãä¼ããã¦ãã¾ãã ãã®æã«ããã®è¿½å æä¸ã¯ä½åå¾ã§ããï¼ã¨èãããã®ã§ããä¸ä½ä½åå¾ãã¯ãæ¥æ¬èçåè°ä¼ã®ã¬ã¤ãã©ã¤ã³ãæ¢ãã¦ãæ¸ãã¦ããã¾ãããææ¥èçæ³ã®æé2010ã«ãæ¸ããã¦ãã¾ãããå°ã£ããå°ã£ãã¨æã£ã¦ãããã2015年度çã®ACLSã®ããã¥ã¢ã«ã«3ãã5åå¾ã¨æ¸ãã¦ããã¾ããããªã¼ï¼ã¨æåããã®ã§ããã2010年度çãè¦ãããåãããã«ã¡ããã¨æ¸ããã¦ãã¾ãããããï¼ä½åº¦ãè¦ãã¯ããªã®ã«ã ããã
ç é¢å å¿åæ¢ã¨ãç é¢å¤å¿åæ¢ãæ¦å¿µçã«åãåããã®ãèçã¬ã¤ãã©ã¤ã³2015ã®æ大ã®ãã¤ã³ãããªã¨æãã®ã§ãããAHAã¬ã¤ãã©ã¤ã³ã®ã¢ã«ã´ãªãºã ã¨ãã¦ã¯ããã¾ãã¡ãã®éããæããããªãã®ãæ®å¿µã ãã®ç¹ãã¨ã¼ãããçã®ERCèçã¬ã¤ãã©ã¤ã³2015ã®ç é¢å å¿åæ¢ã¢ã«ã´ãªãºã ã¯ããå ·ä½çã§ãã å ¥ãå£ãå¿åæ¢ãåããååã«éãããSick Patientãã¤ã¾ãå ·åã®æªãããªæ£è ãè¦ãã¨ããã¨ããããã¹ã¿ã¼ããã¦ãã¾ãã çå½å¾´åããªããã°30ï¼2ã®CPRã§ãããçå½å¾´åãããå ´åã¯ãABCDEã¢ããã¼ãã§ä½ç³»çãªã¢ã»ã¹ã¡ã³ãããã¦ãç æ èªèã¨å¦ç½®ãããã¨ã ãã®å¦ç½®ã¨ããã®ã¯é ¸ç´ æä¸ã¨éè路確ä¿ã®ãã¨ã ãããã£ã¦æä½éã®å®å®åã§å¿åæ¢ãé£ãæ¢ãã¤ã¤ãèçãã¼ã ã«å¼ãç¶ãã¨ããå 容ã å®å ¨ã«PEARSã§ããã å¿åæ¢äºé²ã®ã¢ãã¿ãªã³ã°ãBLSãããã¤ãã¼ï¼è±èªç表è¨ã§ã¯Primary Pr
AHA-BLSã¤ã³ã¹ãã©ã¯ã¿ã¼æ¥è¨ ï½ å¿èºèçæè²æåç· ã¢ã¡ãªã«å¿èåä¼(AHA)ã®ä¸æ¬¡æå½å¦ç½®(BLS)ã¤ã³ã¹ãã©ã¯ã¿ã¼ã®è¦ç¹ã§è¦ãææ¥å¿èºèçäºæ æåç·ãã¬ã¤ãã©ã¤ã³2015ãæ¿åããèçæè²ã®ä»ã綴ã£ã¦ãã¾ããAHAã¤ã³ã¹ãã©ã¯ã¿ã¼ã«ãªãæ¹æ³ãä»ã ãã¤ã¦ã¯ãããå¾ãªãï¼ãã¨è¨ããã¦ããçè·å¸«ã®ACLSã¤ã³ã¹ãã©ã¯ã¿ã¼ã ã»ãã®æ°å¹´ã®ãã¡ã«ãåºãããè¦ãã¦ããã¾ã§ã¯ã»ã¼ãã¹ã¦ã®ITCã§èªããããããã«ãªã£ã¦ããããã§ãã ãã ãçè·å¸«ã主ä½ã¨ãªã£ã¦éå¬ããACLSãããã¤ãã¼ã³ã¼ã¹ã¯ãã¾ã å¤ãã¯ããã¾ããã BLSããããªãç é¢ã§ã®æ¥åçµäºå¾ã«ãæ¾èª²å¾ã³ã¼ã¹ãã¨ãã¦æ°è»½ã«éå¬ã§ãã¾ãããACLSã¨ããªãã¨æéçãªé¢ã¯ãã¨ãããæ©æã®æºåã¨ããç¹ã§ããã²ã¨ãã§ç´°ã ã¨éå¬ããã«ã¯ãªããªãã¿ã¤ãã³ã ã¾ãç é¢å¤ã§å人çã«ACLSãéå¬ãããã¨æã£ãã¨ãã«ãALSãããã³ã®ã¬ã³ã¿ã«ã¯ãã
ææ¥ç§å°éå»ã®è³æ ¼ãæã¤å¤ç§å»ã§ããã¢ã¤ãã«å¥½ãã§ãã®ã§ã¢ã¤ãã«ãã¿ãæ¸ãã¦ãã¾ãï¼é常ã«æã ï¼ãå¥ã®æã«ææ¥ç§å°éå»ã®è©¦é¨åé¡ã®è§£èª¬ãå ¬éãã¦ãã¾ãã ãããæ°ã稼ãããï¼ããã¦æ¥µè«ããæããå¤ã¯æå¹ã§ããåè«ãæ´è¨ããå±è²¬å¤§æè¿ã§ãã æããå¤æå¦ãã¦æå¾ã¾ã§ãããããããã¨è¨ãè¨äºãæè¿ããã¾ããããç§ã¯å¥½ãã§ã¯ããã¾ãããç´æ¥é¢ä¿ããã¾ããããããæå¾ã¾ã§èå°ã«ç«ã£ã¦ãããã ãã§ä½æ ãã¡ãªã®ã§ããããï¼æããå¤ã«å¯¾ãããã¤ãã¹ã¤ã¡ã¼ã¸ãåãä»ãããããªå°è±¡ãããã¾ãã ãæããå¤ã¯å¹ããªããã¨è¨ãã®ã¯ãããéã¯äººããã¡ã«ãããã¨è¨ãã®ã¨åãã§ãããéãä¸æã使ã£ã¦å¹¸ãã«ãªã£ããã大ããªä»äºããªããããå°ã£ã¦ãã人ãå©ããããã人ã¯ãããããã¾ãã確ãã«ãã¡ã«ãªã人ããã¾ããä¸æ¹çãªå ±éã¯é¿ãã¦é ãããã§ãããæã ãéµåã¿ã«ããªãããã«ãããã§ãã ãããããå¹ããå¹ããªãã¨è¨ãã®ã¯
ææ¥ç§å°éå»ã®è³æ ¼ãæã¤å¤ç§å»ã§ããã¢ã¤ãã«å¥½ãã§ãã®ã§ã¢ã¤ãã«ãã¿ãæ¸ãã¦ãã¾ãï¼é常ã«æã ï¼ãå¥ã®æã«ææ¥ç§å°éå»ã®è©¦é¨åé¡ã®è§£èª¬ãå ¬éãã¦ãã¾ãã ããªã³ãã©ã³ï¼ä¸è¬åã¡ãã¯ããã©ããï¼ã¨ããè¬ãããã¾ããåãæ°æ¢ãã®è¬ã§ã注å°è¬ã¨å æãããã¾ãã注å°ã¯ææ¥å¤æ¥ã§ä½¿ããããããã使ããã¦ãã¾ããè³ã«å ¥ããããï¼è³å¹¹ã«ä½ç¨ãã¾ãï¼ã®ã§é«é½¢è ãå°å ã§ã¯éä½å¤è·¯çç¶ã«æ°ãã¤ããã¨ããå¦å©¦ããã«ã¯ãã¡ããããã¨ããè²ã ããã¾ãããç¦å¿ã¨ãã¦ãæ¶å管ã«åºè¡ãç©¿ååã¯å¨è³ªçéå¡ã®ããæ£è [æ¬å¤ã«ã¯æ¶å管éåã®äº¢é²ä½ç¨ããããããçç¶ãæªåããããããããã ã]ãã¨ããã®ãããã¾ãï¼ã¤ã³ã¿ãã¥ã¼ãã©ã¼ã ããï¼ã ããããåããã¤ã³ã¿ãã¥ã¼ãã©ã¼ã ã«ã¯ãå è¦é¡æ¤æ»åã«æä¸ããã¨ãåååå¿ãªã©ãæå¶ããã¦æ¤æ»ãããããããªãï¼75ï¼ ã«æå¹ï¼ã¨ãããã¾ããæ¶å管éåãæ´æ°ãããããã«ãèã®ä¸ã«ããè¡æ¶²
ææ¥ç§å°éå»ã®è³æ ¼ãæã¤å¤ç§å»ã§ããã¢ã¤ãã«å¥½ãã§ãã®ã§ã¢ã¤ãã«ãã¿ãæ¸ãã¦ãã¾ãï¼é常ã«æã ï¼ãå¥ã®æã«ææ¥ç§å°éå»ã®è©¦é¨åé¡ã®è§£èª¬ãå ¬éãã¦ãã¾ãã Facebookã§é常ã«åé¿ããã£ã¦ããããï¼ãç¾å¨930ããã ããã®ã§ããã¡ãã«ãè¼ãã¾ãã ããæ¥ã®æãæ¹ã«çºç±ã®æ£è ããã«å ¥é¢ãã¦ãããã¾ãããç·æ¥å ¥é¢ã¯èª°ã§ãå«ãªãã®ã§ããææ¥å¤æ¥ã®çè·å¸«ããã¯ããã¤ãè¬ããªããç æ£ã«ç³ãéãããã¦ãã¾ãã ææ¥å¤æ¥ã®çè·å¸«ãããããããªæ¤æ¸©ã®å¿ããæéã«æ¸ã¿ã¾ãããã¨è¨ã£ãããç æ£ã®çè·å¸«ããããããããã39度ãç±ãããã°å®¶ã«ã¯å¸°ãã¾ãããã大ä¸å¤«ã§ãããã¨è¨ã£ã¦ãã ãã£ãããã§ãå¤æ¥ã®çè·å¸«ãããåãã§ãã¾ããããã¤ãã¯ãä½ã§ãããªè»½çã®æ£è å ¥é¢ãªã®ï¼ï¼ãã¨è¨ããããã¨ãããããã§ãããã æè¡å®¤ã§ãããã§ãããå»è ã§ããã°ç´¹ä»ãåããå´ã®ç«å ´ï¼ä¸æ¬¡ç é¢ã¨ããâèå¤ç§ã¨ãâç¥âå¤ç§ã¨ããâ液
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}